We bring decades of combined experience investing, operating and transforming healthcare businesses

Mike Lynch

Mike Lynch is a seasoned global executive with over 35 years of strategic and operational experience in medical products manufacturing, sourcing and distribution. Most recently, Mike was Operating Partner at Pritzker Private Capital focused on the firm’s healthcare efforts.

Prior to joining PPC, Mike served as CEO of Cardinal Health’s medical segment, a $10 billion business with more than 15,000 employees in nine countries serving hospitals, clinics and other sites of care worldwide. He held leadership roles in several Cardinal Health businesses, consistently growing them through acquisitions, alliances, organic revenue and operational improvements. Mike is a graduate of Cornell University and serves on the Board of Directors for Boston Centerless and is a former member of the AdvaMed board of directors and its executive committee.

Kent Payne, Ph.D

Kent Payne, Ph.D, is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. Kent combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across biotechnology and pharmaceutical market segments from discovery through cGMP commercial manufacturing. In addition to the U.S., he has successfully led the geographic expansion of businesses into Asia, South America and Europe. Kent previously served as CEO for BioDuro-Sundia. He serves as a board member for Goodwin Biotechnologies. He held prior Board and Advisory roles at Life Science Institute, Technophar, Qualicaps, and PDS Biotechnology.

Prior to joining BioDuro, Kent was CEO at Socorro Pharmaceuticals, a generic pharmaceutical company; President Americas at Qualicaps; Principal Consultant and Partner at CoreFactor executive advisory services; Vice President/General Manager at Catalent Pharma Solutions in addition to posts at Novartis; Monsanto and G.D. Searle.

Michael Dal Bello

Michael Dal Bello is a Partner at Curewell Capital and has been involved in principal investing for over 25 years, primarily focused on the healthcare sector. Prior to co-founding Curewell Capital, Michael was Investment Partner and Head of Healthcare at Pritzker Private Capital, serving on the boards of Clinical Innovations, PathGroup, and KabaFusion. Prior to PPC, Michael was a Managing Director at Blackstone where he focused on healthcare and insurance and served on the boards of Alliant Insurance Services, Apria Healthcare, Biomet, Catalent, Emdeon (now Change Healthcare), TeamHealth and Vanguard Health Systems.  During his tenure he worked with management teams to drive value through operational improvements, growth initiatives and acquisitions. He currently serves on the Board of Directors of Alliance for Multispecialty Research and WeInfuse.

Before joining Blackstone, Michael worked at Hellman & Friedman and Bain & Company. Michael earned an MBA from Harvard Business School and a master’s degree in Philosophy, Politics and Economics from Balliol College at Oxford University where he was a Thouron Scholar. He received his undergraduate degrees from the Wharton School and the College of Arts & Sciences at the University of Pennsylvania. He is a Board Member of the UCLA Technology Development Group and the Luskin Orthopaedic Institute for Children at UCLA and is a former Chairman of the Healthcare Private Equity Association. He is a member of the Council on Foreign Relations.

Ceron Rhee

Ceron Rhee is a Partner at Curewell Capital and brings more than 15 years experience investing in and working with healthcare companies and management teams. Prior to co-founding Curewell Capital, Ceron was an Investment Partner at Pritzker Private Capital where he helped lead the healthcare team. Prior to PPC, Ceron focused on healthcare private equity at TPG Capital and Blackstone, where he was involved with various investments across healthcare services, medical devices and life sciences. Ceron was previously in the healthcare investment banking division at Credit Suisse. He currently serves on the Board of Directors of Alliance for Multispecialty Research and WeInfuse.

Ceron has worked on U.S. healthcare policy supporting the White House Council of Economic Advisers. Ceron has also co-authored a number of research publications, including peer-reviewed health economics articles and original scientific research. Ceron earned an MBA from Stanford Graduate School of Business and also received his undergraduate degrees in Biology and Economics from Stanford University. He is a Term Member of the Council on Foreign Relations.

Alan Muney, MD MHA

Alan Muney is a physician and executive leader with more than 35 years of experience leading healthcare payor and provider organizations. Prior to Curewell Capital, Alan was Senior Advisor for Healthcare at Pritzker Private Capital.

Alan previously served as Cigna’s Chief Medical Officer and EVP of Total Health and Network, where he oversaw clinical strategy, coverage policy, quality measurement and improvement, and total health physician and clinical operations. Alan also oversaw Cigna’s team of doctors, dentists, nurses and behavioral health clinicians involved in the company’s health management and wellness programs. Before joining Cigna, Alan was an Executive Director in the Private Equity Group at Blackstone, and the CEO of Equity Healthcare, which he founded to manage the healthcare costs of Blackstone’s portfolio companies. While at Blackstone, he also served on the Board of Directors of Vanguard Health System and Team Health. Prior to Blackstone, Alan was EVP and Chief Medical Officer of Oxford Health Plans and Chief Medical Officer of United Healthcare of the Northeast region from 1998-2007. Alan also held leadership positions at Avanti Health systems, a division of NYLCare health plans, and Mullikin Medical Centers, a large multi-specialty medical group in California.

Board-certified in pediatrics, Alan received his B.S. in Biology, his MD from Brown University, and a Master in Health Administration from the University of La Verne. He is also a frequent lecturer on issues in managed health care.

Apurva Srivastav

Apurva Srivastav is a Vice President at Curewell Capital and is closely involved with the firm’s investments in Alliance for Multispecialty Research and WeInfuse. Apurva was most recently an Associate at Pritzker Private Capital, where he focused on healthcare investing across a variety of subsectors including healthcare services, healthcare IT and pharma services.

Prior to PPC, Apurva was an Associate at CIT Group where he provided analytical support for the financing of leveraged buyouts of middle market healthcare companies. Apurva also previously held positions at Janssen Pharmaceuticals, a division of Johnson & Johnson. Apurva received his undergraduate degree in Chemical Engineering from Rutgers University.

Adam Narwicz

Adam Narwicz is a Vice President at Curewell Capital. Adam was most recently a Senior Associate at Pritzker Private Capital, where he focused on healthcare investing across a variety of subsectors including healthcare services, medical devices, pharma services, and life sciences.

Prior to PPC, Adam was an Investment Banking Associate in the Global Healthcare Group at Citigroup where he provided analytical support on mergers, acquisitions, leveraged buyouts, financings and other financial advisory services to public and private healthcare companies. Adam also previously held positions at GE Capital.  Adam received his undergraduate degree in Economics from Gettysburg College.

David King

David King brings over 30 years of leadership and operational experience running and advising global healthcare companies. Most recently, David was Operating Partner at Pritzker Private Capital focused on the firm’s healthcare efforts.

Prior to joining PPC, David was CEO and Chairman at LabCorp (NYSE: LH), a leading global life sciences company. Under David’s leadership, LabCorp grew to be the world’s largest clinical laboratory and second-largest drug development business with the acquisition and expansion of Covance. Prior to LabCorp, David was an attorney and partner at Hogan & Hartson (now Hogan Lovells) helping lead the firm’s national healthcare practice. He currently serves as Chairman of the Board of Directors of Alliance for Multispecialty Research. He also serves on a number of other public and private company boards. David earned his JD from the University of Pennsylvania Law School and his undergraduate degree from Princeton University.

Paula Brown Stafford

Paula Brown Stafford is a biopharmaceutical executive and leadership consultant with more than 35 years of industry experience. She is currently the President, CEO and Chairman of the Board of Novan, Inc. (NASDAQ: NOVN), a clinical development-stage biotechnology company. Additionally, she currently serves on the Board of Directors of Alliance for Multispecialty Research.

Prior to joining Novan, Paula served as President of Clinical Development and was on the Executive Committee at Quintiles (now IQVIA, NYSE: IQV), the world’s largest clinical research organization with a presence in over 100 countries, where she was responsible for global clinical development services. Having joined Quintiles in 1985, Paula helped build Quintiles into the preeminent CRO in the industry over her 30-year tenure at the company. Paula is also a co-founder and Managing Director for Habergeon LLC and an adjunct professor in Public Health Leadership for the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, where she was a Past President of the Public Health Foundation Board. She previously served on the board of Health Decision, CDISC (Clinical Data Interchange Standards Consortium), Bio-Imaging Technologies, Inc. (Nasdaq: BITI and later BIOC). Paula holds a B.S. and a Master of Public Health from the University of North Carolina at Chapel Hill, with a specialization in Biostatistics.

George Lazenby

George Lazenby is an entrepreneur and executive leader with over 25 years of experience in the field of healthcare information technology. He is Co-Founder and CEO of OrderInsite, a leading provider of cloud-based supply chain and inventory management software for the pharmacy industry.

Prior to OrderInsite, George was CEO of Emdeon (now Change Healthcare, acquired by Optum), the nation’s largest health information network in the U.S.  George led Emdeon through significant growth and change, including completing over 15 acquisitions, making the company a clear leader in its space. Under George’s leadership, Emdeon successfully completed its IPO and subsequent sale to Blackstone.  Prior to Emdeon, George served as COO of Medifax EDI, one of the nation’s leading revenue cycle management companies that was acquired in 2004 by WebMD. George is also a partner in Socii Capital, a venture investment firm focused on the pharmacy IT marketplace with investments in MedOne, RxLogic Solutions, RxLightning, and Thirdwave Innovations. Additionally, George currently serves on the Board of Directors of WeInfuse, ProxsysRx, CarePayment, and Xsolis.